+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres

Haemophilia 9(Suppl. 1): 19-26; Discussion 26

A survey was conducted in 2002 to determine the pattern of factor prophylaxis use in boys or=45 weeks per year, was significantly higher for haemophilia A vs. haemophilia B cases (51% vs. 32%, P< 0.0001), and for boys with severe haemophilia A living in Canada vs. the USA (77% vs. 47%, P< 0.0001). Use of full-dose prophylaxis, defined as the infusion of 25-40 IU kg(-1) of factor VIII on alternate days (minimum three times per week) or 25-40 IU kg(-1) of factor IX twice weekly, was similar for boys

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048126900

Download citation: RISBibTeXText

PMID: 12709033

DOI: 10.1046/j.1365-2516.9.s1.12.x

Related references

Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 18(1): 63-68, 2012

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 13(5): 502-507, 2007

Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia 15(3): 760-765, 2009

Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia 25(4): 668-675, 2019

The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 14(5): 923-930, 2008

Venous thrombosis prophylaxis in haemophilics undergoing major orthopaedic surgery: a survey of haemophilia treatment centres. Haemophilia 15(6): 1337-1338, 2009

FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 15(3): 743-751, 2009

Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres. Pharmacy World and Science 30(3): 287-292, 2008

Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 2(1): 28-31, 1996

Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. British Medical Journal 286(6369): 929-933, 1983

Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthopaedica Scandinavica. Supplementum 1965: Suppl 77:3, 1965

Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. Haemophilia 20(4): E287-E295, 2014

Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A, haemophilia B and von Willebrand's disease. UK Regional Haemophilia Centre Directors Committee. Blood Coagulation & Fibrinolysis 3(2): 205-214, 1992

Treatment trends for haemophilia A and haemophilia B in the United States results from the 21 practice patterns survey. 2012

A patient satisfaction survey for haemophilia treatment centres. Haemophilia 12(2): 163-168, 2006